Rupinder Tewari

Nectar Lifesciences (NecLife) is a pharmaceutical company. The Company is engaged in providing drugs and pharmaceuticals. It operates in the business segment of Pharmaceuticals Products. The Company's business activities include contract research and manufacturing services, active pharmaceutical ingredient (API) and intermediates, formulations, generics and over the counter (OTC), diagnostics, empty hard gelatin capsules and menthol. Its products include Cefixime Trihydrate, Cefuroxime Axetil (Amorphous), Cefpodoxime Proxetil, Cefuroxime Sodium (Sterile), Ceftazidime (Buffered), Cephalothin (Buffered), Cefazolin Sodium (Sterile), Cefprozil, Cefoperzone Sodium (Sterile), Cefpirome Sulphate (Buffered) and Cefoxitin Sodium (Sterile). It offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectible for cephalosporins. Its subsidiaries include Nectar Lifesciences UK Limited and Nectar Lifesciences US, LLC.